File downloaded on 2026-11-09
Source URL: https://medicines.health.europa.eu/veterinary/en/600000080368

Bovilis Bovipast RSP suspension for injection for cattle

Authorised

- Bovine respiratory syncytial virus, strain EV 908, Inactivated
- Bovine parainfluenza virus 3, strain SF-4, Inactivated
- Mannheimia haemolytica, serotype A1, strain M4/1, Inactivated

Product identification

Medicine name:
Bovilis Bovipast RSP suspension for injection for cattle

Active substance:
Bovine respiratory syncytial virus, strain EV 908, Inactivated

Bovine parainfluenza virus 3, strain SF-4, Inactivated

Mannheimia haemolytica, serotype A1, strain M4/1, Inactivated

Target species:
Cattle

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Bovine respiratory syncytial virus, strain EV 908, Inactivated
281838.00 unit(s) / 5.00 millilitre(s)

Bovine parainfluenza virus 3, strain SF-4, Inactivated
70794.60 unit(s) / 5.00 millilitre(s)

Mannheimia haemolytica, serotype A1, strain M4/1, Inactivated
100000.00 unit(s) / 5.00 millilitre(s)

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Cattle**
  - Meat and offal. 0 day
  - Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI02AL04

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Sweden

Available in:
Sweden

Package description:
Available only in Swedish

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
21/03/2003

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Swedish Medical Products Agency

Authorisation number:
18894

Date of authorisation status change:
21/03/2003

Reference member state:
Ireland

Procedure number:
IE/V/0537/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Denmark Finland France Greece Hungary Italy Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 25/09/2024
Updated on: 14/03/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

Labelling

This document does not exist in this language (English). You can find it in another language below.